Accelerating
Flu Lab is pursuing novel, transformative approaches to advance new products, new methods, and new knowledge. Investments in this area include efforts to draw attention to the pressing need for a universal influenza vaccine and to expand the research disciplines and scientific approaches involved in the pursuit of new influenza medical countermeasures.
Universal Influenza Vaccine Candidates
Flu Lab, in collaboration with the Bill & Melinda Gates Foundation, launched the Grand Challenge for Universal Influenza Vaccine Development, offering USD $12 million in seed money for novel, transformative approaches to developing a universal influenza vaccine. Flu Lab co-funds this important effort to expand the research disciplines and scientific approaches involved in the pursuit of a universal influenza vaccine. Our grantees represent a diverse set of backgrounds, areas of expertise, and geographies and they are approaching the challenge in new and exciting ways.
Universal Influenza Vaccine Innovation
Flu Lab supports the Sabin Vaccine Institute and its efforts to draw attention to the pressing need for a universal influenza vaccine and bring new perspectives to invigorate influenza research. Flu Lab support enabled the establishment of the Sabin-Aspen Vaccine Science & Policy Group, which convened in 2018 to explore challenges and opportunities to develop a universal influenza vaccine. The group’s recommendations on how to overcome the scientific, financial and organizational barriers to developing a vaccine are synthesized in the report Accelerating the Development of a Universal Influenza Vaccine.